TY - JOUR AB - Canine oral malignant melanoma (COMM) is the most aggressive malignant tumor in dogs. Lupeol is a triterpene extracted from various fruits and vegetables that reportedly inhibits melanoma cell proliferation in vitro and in vivo. In this study, the efficacy of subcutaneous lupeol for spontaneous COMM was evaluated. A total of 11 dogs (3, 5 and 3 dogs diagnosed with clinical stage I, II and III melanoma, respectively) were evaluated. Subcutaneous lupeol (10 mg/kg) was administered postoperatively at various time points to treat these 11 COMM cases. of the 11 subjects, 7 exhibited no local recurrence 180 days postoperatively and no severe adverse effects were observed in any of the cases. Furthermore, no distant metastasis was observed during the experimental period. Therefore, systemic lupeol may prevent local tumor progression and distant metastasis and may be a novel adjuvant treatment for the treatment of COMM. AD - School of Veterinary Medicine, Faculty of Agriculture, Tottori University, Tottori 680‑8553, Japan Institute for Food and Brewing, Akita Prefectural Agricultural, Forestry and Fisheries Research Center, Akita 010‑1623, Japan Sakamoto Bio Co., Ltd., Yuuwa‑Memeki, Akita 010‑1233, Japan AU - Yokoe,Inoru AU - Azuma,Kazuo AU - Hata,Keishi AU - Mukaiyama,Toshiyuki AU - Goto,Takahiro AU - Tsuka,Takeshi AU - Imagawa,Tomohiro AU - Itoh,Norihiko AU - Murahata,Yusuke AU - Osaki,Tomohiro AU - Minami,Saburo AU - Okamoto,Yoshiharu DA - 2015/01/01 DO - 10.3892/mco.2014.450 EP - 92 IS - 1 JO - Mol Clin Oncol KW - canine melanoma lupeol systemic injection survival time PY - 2015 SN - 2049-9450 2049-9469 SP - 89 ST - Clinical systemic lupeol administration for canine oral malignant melanoma T2 - Molecular and Clinical Oncology TI - Clinical systemic lupeol administration for canine oral malignant melanoma UR - https://doi.org/10.3892/mco.2014.450 VL - 3 ER -